Abstract. Introduction: The MPAL comprise 2 classification has separated two groups in MPAL based on t(9;22) positivity and MLL rearrangement. Aims & Objectives: BCR-ABL transcript in MPAL cases using the RT hematological remission post induction. on Flow-cytometry based on the current WHO 2008 criteria were enrolled. In all the cases Bone marrow or peripheral blood sample in EDTA was processed for molecular studies and the RT reaction carried out using primers specific to the t (9;22) and t(4;11) tra induction check marrow slides were also reviewed. (70%) were adult and 3/10 (30%) pediatric cases. A total of 4/10 (40%) cases showed positivity for the t(9;22) transcript and none for t (4 1/10(10%) pediatric case. The BCR (66%) and e1a2 (p190) in 1/3 (33.3%) case. The single pediatric case was positive for b3a2 transcript. Discussion & Conclusion: low platelet count (p<0.05). The positive cases also showed hematological remission at post induction check marrow (blasts<5%). This could partly be explained due to good r imatinib added to the treatment protocol.
Introduction. Acute leukemia with a mixed phenotype is a rare disease and comprises 2-5% of all acute In all the cases Bone marrow or peripheral blood sample in EDTA was processed for molecular studies and the RT reaction carried out using primers specific to the t (9;22) and t(4;11) tra induction check marrow slides were also reviewed. Results: Out of the total 10 MPAL cases, 7/10 (70%) were adult and 3/10 (30%) pediatric cases. A total of 4/10 (40%) cases showed positivity for the t(9;22) transcript and none for t (4;11). Of the 4 positive cases, 3/10(30%) were adult cases and 1/10(10%) pediatric case. The BCR-ABL transcript type in adult cases was b3a2 (p210) in 2/3 (66%) and e1a2 (p190) in 1/3 (33.3%) case. The single pediatric case was positive for b3a2
Discussion & Conclusion: All the 4 positive MPAL cases presented with high TLC and low platelet count (p<0.05). The positive cases also showed hematological remission at post induction check marrow (blasts<5%). This could partly be explained due to good r imatinib added to the treatment protocol. Methodology. RNA was extracted from 1-2ml Bone Marrow aspirate in EDTA or 3-5ml Peripheral blood (if blasts > 20% and TLC> 50X10 9 /L) using the commercial kit (Qiagen Miniamp RNA Blood kit) according to manufacturer's instructions. The RNA quality was checked in each case by absorbance at 260nm in a spectrophotometer and by running a 1% formaldehyde gel for 18s and 28s RNA bands. This was followed by cDNA synthesis according to the commercial kit protocol (Fermantas cDNA kit). The quality of cDNA was checked using primers for β-Actin housekeeping gene.
Reverse Transcriptase polymerase chain reaction was carried out using primers specific for p210 (b3a2 and b2a2) 2 adapted from the study of Jones et al and the protocol was standardized in our laboratory in 2004 for detection of p210 transcript in CML cases. A separate Multiplex RT-PCR was done for detection of p190 and MLL-AF4 transcript as adapted from study by Pakakasama et al 3 . This Multiplex RT-PCR is routinely used in our laboratory as a screening PCR for detection of common chimeric fusion transcripts in ALL cases. The PCR conditions for both the PCR are outlined below and the primer sequences and the product base size are highlighted in the table 1. The BCR-ABL PCR for p210 transcripts (b3a2 and b2a2) was carried out in following conditions: Pre-Denaturation-94c-4 mtsone cycle; Denaturation-94c-1 mt, Annealing-63c-2 mt and Extension-72c-3 mt for 32 cycles. This was followed by one cycle of final Extension at 72c-10 mt. The Multiplex RT-PCR for p190 (e1a2) transcript and the MLL-AF4 transcript was carried out as follows:
The Ethical Justification. The blood sample used in the study is withdrawn as a part of routine diagnostic work-up of the patient and no additional sample pricks were performed. Prior informed consent was taken from all patients/guardians before withdrawl of sample. Results. The total frequency of MPAL was 6% (10/170) of all acute leukemia cases that underwent routine diagnostic evaluation during the study period. Out of the 10 MPAL cases, 7/10 (70%) were adult and 3/10 (30%) were Pediatric cases. The age in adult cases ranged from 26-60 years (Mean age 31.5 yrs) and M: F ratio was 1.3:1. The age in Pediatric cases ranged from 7 months -7 years (Mean age 3.7 years) and all were Male children. The clinical and Hematological data of the MPAL cases is outlined in table 2.
On Immunophenotyping, 60% (6/10) were B/Myeloid and 40% (4/10) were T/Myeloid. The incidence of BCR-ABL positivity in MPAL cases was 40% (4/10). All four MPAL cases positive for BCR-ABL transcript presented with High TLC and Low platelet count (p value ≤0.05). 3/4 (75%) BCR-ABL positive MPAL's had B/Myeloid phenotype while 1/4 (25%) had T/Myeloid phenotype. Molecular breakpoint was p210 (b3a2 type) in 3/4 (75%) cases and p190 in 1/4 (25%) case. The Immunophenotyping, molecular and remission data in MPAL cases is detailed in table 3. Cytogenetics revealed satisfactory metaphases in 6/10 cases. Philadelphia positive metaphases were noted in all four BCR-ABL positive MPAL cases with a 100% correlation. However, no additional cytogenetic abnormality could be identified in any of the cases. Discussion. In the present study all the MPAL cases positive for BCR-ABL transcript had high WBC count and low platelet count (p<0.05). Many studies have also shown BCR-ABL positive MPAL's presenting with high WBC count 4, 5 , but present study also shows relation of BCR-ABL positivity with low platelet count. There were 4 cases of T/Myeloid MPAL,of which one showed BCR-ABL positivity (Figure 3) . Mastutes et al 6 in their study had also found BCR-ABL positivity in 13% (2/15) cases with T/Myeloid phenotype.
The incidence of MPAL cases was 6% and the BCR-ABL positivity in present study was 40% which is quiet comparable to few other studies from the subcontinent and west. Studies from Asian subcontinent by Xu in MPAL cases; 30% cases had no follow-up details while 20% were not in CHR. Of the four BCR-ABL were positive for b3a2 transcript type (p<0.05%). Only one BCR-ABL positive MPAL (p190 transcript) showed 60% blasts in Bone marrow at 1 st check marrow. However, the case number and positivity for p190 transcript is low and the follow-up data is limited to derive any conclusive statement regarding prognostic difference between the two transcript types in MPAL cases. The MPAL cases are treated with ALL/AML standard induction protocol based on predominant Blast immunophenotype. In addition Imatinib is added to the treatment regimen if the MPAL case is BCR-ABL positive on RT-PCR. All the above four BCR-ABL positive MPAL cases received Imatinib along with standard induction regimen drugs. The good response in three cases could be attributed to the possible favorable effect of Imatinib addition to the standard induction regimen, which is quiet well described in literature . However long term follow up data in more number of cases is needed to further substantiate the findings. None of our MPAL case was positive for MLL-AF4 transcript. However we had not looked for other MLL rearrangements in these cases.
Conclusions.
Immunophenotyping of all acute leukemia cases is necessary with a complete panel of lineage specific markers to detect presence of Mixed Phenotype Acute leukemias. RT-PCR for BCR-ABL is also mandatory in all MPAL cases as the overall prognosis in these patients may improve with addition of Imatinib (Gleevac /STI571) therapy to the treatment regimen.
